277 related articles for article (PubMed ID: 29620212)
1. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.
Sui X; Sui Y; Wang Y
Mol Med Rep; 2018 Jun; 17(6):7521-7528. PubMed ID: 29620212
[TBL] [Abstract][Full Text] [Related]
2. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
[TBL] [Abstract][Full Text] [Related]
3. FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway.
Ma S; Wang Q; Ma X; Wu L; Guo F; Ji H; Liu F; Zhao Y; Qin G
Tumour Biol; 2016 Jan; 37(1):989-98. PubMed ID: 26264613
[TBL] [Abstract][Full Text] [Related]
4. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
5. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
6. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
7. Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma.
Wei S; Gao M; Zhao C; Pan Y; Li H; Li J; Li X
Int J Clin Oncol; 2014 Oct; 19(5):800-4. PubMed ID: 24096868
[TBL] [Abstract][Full Text] [Related]
8. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.
Shen CT; Qiu ZL; Song HJ; Wei WJ; Luo QY
J Exp Clin Cancer Res; 2016 Jun; 35(1):101. PubMed ID: 27342319
[TBL] [Abstract][Full Text] [Related]
9. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
12. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
13. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
14. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
16. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
18. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.
He J; Jin Y; Zhou M; Li X; Chen W; Wang Y; Gu S; Cao Y; Chu C; Liu X; Zou Q
Cancer Sci; 2018 Mar; 109(3):642-655. PubMed ID: 29274137
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory roles of miR‑9 on papillary thyroid cancer through targeting BRAF.
Gu Y; Yang N; Yin L; Feng C; Liu T
Mol Med Rep; 2018 Jul; 18(1):965-972. PubMed ID: 29767243
[TBL] [Abstract][Full Text] [Related]
20. The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.
Kotlarek M; Kubiak A; Czetwertyńska M; Świerniak M; Gierlikowski W; Kolanowska M; Bakuła-Zalewska E; Jhiang SM; Jażdżewski K; Wójcicka A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
